Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial


Easton J. D. , Lopes R. D. , Bahit M. C. , Wojdyla D. M. , Granger C. B. , Wallentin L., ...More

LANCET NEUROLOGY, vol.11, no.6, pp.503-511, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11 Issue: 6
  • Publication Date: 2012
  • Doi Number: 10.1016/s1474-4422(12)70092-3
  • Title of Journal : LANCET NEUROLOGY
  • Page Numbers: pp.503-511

Abstract

Background In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.